|
WO1990004633A1
(en)
|
1988-10-21 |
1990-05-03 |
Brigham And Women's Hospital |
ACTIVATION AND GROWTH OF HUMAN TUMOR-INFILTRATING LYMPHOCYTES USING ANTIBODIES TO CD3 OR TcR
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
US5126132A
(en)
|
1989-08-21 |
1992-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Tumor infiltrating lymphocytes as a treatment modality for human cancer
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5222982A
(en)
|
1991-02-11 |
1993-06-29 |
Ommaya Ayub K |
Spinal fluid driven artificial organ
|
|
JPH06505186A
(ja)
|
1991-02-11 |
1994-06-16 |
オマーヤ，アユブ ケー． |
脊髄液駆動式人工器官
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
US5356802A
(en)
|
1992-04-03 |
1994-10-18 |
The Johns Hopkins University |
Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
|
|
US5436150A
(en)
|
1992-04-03 |
1995-07-25 |
The Johns Hopkins University |
Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
|
|
US5487994A
(en)
|
1992-04-03 |
1996-01-30 |
The Johns Hopkins University |
Insertion and deletion mutants of FokI restriction endonuclease
|
|
EP0705344B8
(en)
|
1993-06-24 |
2006-05-10 |
Advec Inc. |
Adenovirus vectors for gene therapy
|
|
AU687117B2
(en)
|
1993-10-25 |
1998-02-19 |
Canji, Inc. |
Recombinant adenoviral vector and methods of use
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US7078387B1
(en)
|
1998-12-28 |
2006-07-18 |
Arch Development Corp. |
Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
GB9927328D0
(en)
|
1999-11-18 |
2000-01-12 |
Lorantis Ltd |
Immunotherapy
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
KR20030032922A
(ko)
|
2000-02-24 |
2003-04-26 |
싸이트 테라피스 인코포레이티드 |
세포의 동시 자극 및 농축
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6962810B2
(en)
|
2000-10-31 |
2005-11-08 |
University Of Notre Dame Du Lac |
Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
|
|
WO2002088346A2
(en)
|
2001-05-01 |
2002-11-07 |
National Research Council Of Canada |
A system for inducible expression in eukaryotic cells
|
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US8034334B2
(en)
|
2002-09-06 |
2011-10-11 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
|
|
US7381405B2
(en)
|
2002-10-15 |
2008-06-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer
|
|
AU2003295600A1
(en)
*
|
2002-11-14 |
2004-06-15 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
WO2005118788A2
(en)
|
2004-05-27 |
2005-12-15 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
AU2005336093B2
(en)
|
2004-10-08 |
2011-02-24 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Adoptive immunotherapy with enhanced T lymphocyte survival
|
|
EP1991663A2
(en)
|
2006-03-06 |
2008-11-19 |
Government of the United States of America, Represented by the Secretary, Department of Health and Human Services |
Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
|
|
DK2019683T4
(da)
|
2006-04-25 |
2022-08-29 |
Univ California |
Indgivelse af vækstfaktorer til behandling af CNS-lidelser
|
|
WO2008060360A2
(en)
|
2006-09-28 |
2008-05-22 |
Surmodics, Inc. |
Implantable medical device with apertures for delivery of bioactive agents
|
|
FR2911346B1
(fr)
|
2007-01-12 |
2012-12-07 |
Ct Hospitalier Universitaire De Nantes |
Procede de culture in vitro de lymphocytes t,en particulier de lymphocytes t infiltrant les tumeurs dits til
|
|
US20130331294A1
(en)
|
2007-11-09 |
2013-12-12 |
Fox Chase Cancer Center |
Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
|
|
JP5397692B2
(ja)
|
2007-11-28 |
2014-01-22 |
国立大学法人名古屋大学 |
悪性黒色腫抗原の発現上昇剤及びその用途
|
|
JP2011505144A
(ja)
|
2007-11-30 |
2011-02-24 |
ベイラー カレッジ オブ メディシン |
樹状細胞ワクチン組成物およびその使用
|
|
WO2009097468A2
(en)
|
2008-01-29 |
2009-08-06 |
Kliman Gilbert H |
Drug delivery devices, kits and methods therefor
|
|
US20120052003A9
(en)
|
2008-05-16 |
2012-03-01 |
Szalay Aladar A |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
JPWO2010098429A1
(ja)
*
|
2009-02-27 |
2012-09-06 |
国立大学法人大阪大学 |
免疫アジュバント組成物、及びその利用
|
|
US20120072123A1
(en)
|
2009-05-29 |
2012-03-22 |
Merck & Co., Inc. |
Methods of Predicting The Probability of Modulation of Transcript Levels By RNAI Compounds
|
|
EP2445538A2
(en)
|
2009-06-23 |
2012-05-02 |
University Of Miami |
Aptamer-targeted sirna to inhibit nonsense mediated decay
|
|
US8383099B2
(en)
|
2009-08-28 |
2013-02-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adoptive cell therapy with young T cells
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
US9233125B2
(en)
|
2010-12-14 |
2016-01-12 |
University Of Maryland, Baltimore |
Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
|
|
US20120244133A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States of America, as represented by the Secretary, Department of Health and |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
PT2768942T
(pt)
|
2011-10-17 |
2020-01-21 |
Massachusetts Inst Technology |
Entrega intracelular
|
|
US9226936B2
(en)
|
2011-10-28 |
2016-01-05 |
The Wistar of Anatomy and Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
|
|
JP6062371B2
(ja)
|
2011-11-18 |
2017-01-18 |
公益財団法人東京都医学総合研究所 |
神経変性疾患関連タンパク質の不溶性凝集体の製造方法
|
|
US20150017136A1
(en)
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
AU2013329186B2
(en)
|
2012-10-10 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
WO2014066137A1
(en)
|
2012-10-22 |
2014-05-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for enhancing cancer immunotherapy
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
EP3031921B1
(en)
|
2012-12-12 |
2025-03-12 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
RU2662932C2
(ru)
|
2013-03-14 |
2018-07-31 |
Карибо Биосайенсиз, Инк. |
Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
|
|
CA3051222C
(en)
|
2013-06-10 |
2023-01-24 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for reducing immunosupression by tumor cells
|
|
US20150017120A1
(en)
|
2013-06-13 |
2015-01-15 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
|
|
MX374532B
(es)
|
2013-06-17 |
2025-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
|
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
US10233425B2
(en)
|
2013-09-16 |
2019-03-19 |
The Trustees Of The University Of Pennsylvania |
CD137 enrichment for efficient tumor infiltrating lymphocyte selection
|
|
WO2015048577A2
(en)
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
JP2016540033A
(ja)
|
2013-09-30 |
2016-12-22 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ |
新規ケモカイン受容体、ｃｘｃｒ８の同定
|
|
CN105814083A
(zh)
|
2013-10-15 |
2016-07-27 |
加州生物医学研究所 |
嵌合抗原受体t细胞开关和其用途
|
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
|
CN106459995B
(zh)
|
2013-11-07 |
2020-02-21 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
CA2930877A1
(en)
|
2013-11-18 |
2015-05-21 |
Crispr Therapeutics Ag |
Crispr-cas system materials and methods
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
JP7103750B2
(ja)
|
2013-12-12 |
2022-07-20 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
WO2015127548A1
(en)
|
2014-02-28 |
2015-09-03 |
The Royal Institution For The Advancement Of Learning / Mcgill University |
Tc-ptp inhibitors as apc activators for immunotherapy
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
AU2015231041B2
(en)
|
2014-03-20 |
2020-07-16 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Tumor-infiltrating lymphocytes for adoptive cell therapy
|
|
WO2015154065A1
(en)
|
2014-04-05 |
2015-10-08 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination
|
|
WO2015157636A1
(en)
|
2014-04-10 |
2015-10-15 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
|
|
WO2015161276A2
(en)
|
2014-04-18 |
2015-10-22 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
EP3154555A4
(en)
|
2014-06-10 |
2018-02-28 |
Monash University |
Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
|
|
CA2954791C
(en)
|
2014-07-14 |
2025-11-18 |
The Regents Of The University Of California |
CRISPR/CAS TRANSCRIPTIONAL MODULATION
|
|
ES2841274T3
(es)
|
2014-08-04 |
2021-07-07 |
Hutchinson Fred Cancer Res |
Inmunoterapia con células T específica para WT-1
|
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
WO2016073748A1
(en)
|
2014-11-05 |
2016-05-12 |
Board Of Regents, The University Of Texas System |
Biomarkers and targets for cancer immunotherapy
|
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
|
WO2016123578A1
(en)
|
2015-01-30 |
2016-08-04 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
|
EP3274454B1
(en)
|
2015-03-25 |
2021-08-25 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
|
CN107614012A
(zh)
|
2015-04-24 |
2018-01-19 |
加利福尼亚大学董事会 |
使用工程化的细胞检测、监测或治疗疾病或病况的系统及制备和使用它们的方法
|
|
US20190119635A1
(en)
|
2015-05-05 |
2019-04-25 |
Fate Therapeutics, Inc. |
Modulation of t lymphocytes
|
|
CA2985650A1
(en)
|
2015-05-13 |
2016-11-17 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Enhancing endonuclease based gene editing in primary cells
|
|
KR102349677B1
(ko)
|
2015-05-28 |
2022-01-12 |
카이트 파마 인코포레이티드 |
T 세포 요법을 위해 환자를 컨디셔닝하는 방법
|
|
CA3001683C
(en)
|
2015-06-05 |
2024-06-04 |
The Regents Of The University Of California |
Methods and compositions for generating crispr/cas guide rnas
|
|
US10358467B2
(en)
|
2015-06-09 |
2019-07-23 |
The Regents Of The University Of California |
Therapeutic targets for cancer progression
|
|
WO2017004153A1
(en)
|
2015-06-29 |
2017-01-05 |
The Broad Institute Inc. |
Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
|
|
WO2017008019A1
(en)
|
2015-07-08 |
2017-01-12 |
The Johns Hopkins University |
Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy
|
|
CA2992551A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2017070042A1
(en)
|
2015-10-20 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing t cell populations using akt inhibitors
|
|
KR20180063320A
(ko)
|
2015-10-20 |
2018-06-11 |
카이트 파마 인코포레이티드 |
T 세포 요법을 위한 t 세포를 제조하는 방법
|
|
EP3368687B1
(en)
|
2015-10-27 |
2021-09-29 |
The Broad Institute, Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017079113A1
(en)
|
2015-11-02 |
2017-05-11 |
The United States Of America, As Represented By The Secretary, Department Of Healh And Human Services |
Methods of producing t cell populations using prolyl hydroxylase domain-containing protein inhibitors
|
|
GB201519340D0
(en)
|
2015-11-02 |
2015-12-16 |
Cambridge Entpr Ltd |
Methods of T-lymphocyte expansion
|
|
BE1023924B1
(nl)
|
2015-12-09 |
2017-09-13 |
Stairsolutions Vof |
Systeem van elementen voor het samenstellen van een trap en een trap samengesteld met elementen van zulk systeem
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
WO2017117521A1
(en)
|
2015-12-31 |
2017-07-06 |
Berkeley Lights, Inc. |
Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide
|
|
CN106967685B
(zh)
|
2016-01-13 |
2020-06-02 |
北京马力喏生物科技有限公司 |
共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
|
|
CN106967681B
(zh)
|
2016-01-13 |
2020-06-05 |
北京马力喏生物科技有限公司 |
治疗脑胶质母细胞瘤的治疗组合物
|
|
IL287889B2
(en)
|
2016-02-05 |
2024-03-01 |
Hope City |
Administration of engineered t cells for treatment of cancers in the central nervous system
|
|
AU2017221437A1
(en)
|
2016-02-19 |
2018-08-23 |
Genisphere Llc |
Nucleic acid carriers and therapeutic methods of use
|
|
GB201602974D0
(en)
|
2016-02-19 |
2016-04-06 |
Clube Jasper R |
Engineered cells & methods (1)
|
|
JP2019509738A
(ja)
|
2016-03-11 |
2019-04-11 |
ブルーバード バイオ， インコーポレイテッド |
ゲノム編集された免疫エフェクター細胞
|
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
|
EP3228701A1
(en)
|
2016-04-05 |
2017-10-11 |
Fundación Centro Nacional de Investigaciones Oncológicas Carlos III |
Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof
|
|
KR20180133442A
(ko)
|
2016-04-13 |
2018-12-14 |
비비아 바이오테크 에스.엘. |
생체외 bite 활성화된 t 세포
|
|
WO2017191504A1
(en)
|
2016-05-03 |
2017-11-09 |
Oslo University Hospital Hf |
Validation of therapeutic t-cells
|
|
WO2017210677A1
(en)
|
2016-06-03 |
2017-12-07 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1α) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS)
|
|
US9944331B2
(en)
|
2016-06-09 |
2018-04-17 |
Ford Global Technologies, Llc |
Perforated deformation region for a vehicle hood
|
|
EP3475706B1
(en)
|
2016-06-27 |
2021-08-11 |
Juno Therapeutics, Inc. |
Mhc-e restricted epitopes, binding molecules and related methods and uses
|
|
US20200182884A1
(en)
|
2016-06-27 |
2020-06-11 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
|
MA45595A
(fr)
|
2016-07-07 |
2019-05-15 |
Iovance Biotherapeutics Inc |
Protéines de liaison au ligand (1) de mort programmée (1) (pd-l1) et leurs procédés d'utilisation
|
|
CN107586341A
(zh)
|
2016-07-08 |
2018-01-16 |
生命序有限公司 |
重组免疫检查点受体及免疫检查点抑制分子的共表达及应用
|
|
US10711312B2
(en)
|
2016-07-12 |
2020-07-14 |
The Regents Of The University Of California |
Methods for immunotherapy-based treatment and assessment of cancer
|
|
EP3518976A4
(en)
|
2016-07-15 |
2020-12-16 |
Tufts Medical Center |
COMPOUNDS AND METHODS FOR IMPROVING THE FUNCTION OF THE IMMUNE SYSTEM.
|
|
WO2018024895A1
(en)
|
2016-08-05 |
2018-02-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Immunotherapeutic uses of ex vivo generated foxp3+ regulatory t cells
|
|
AU2017312132A1
(en)
|
2016-08-19 |
2019-03-21 |
Bluebird Bio, Inc. |
Genome editing enhancers
|
|
WO2018039333A1
(en)
|
2016-08-23 |
2018-03-01 |
Bluebird Bio, Inc. |
Tim3 homing endonuclease variants, compositions, and methods of use
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
KR102451510B1
(ko)
|
2016-09-08 |
2022-10-07 |
2세븐티 바이오, 인코포레이티드 |
Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
|
|
US11524988B2
(en)
|
2016-09-19 |
2022-12-13 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Artificial antigen presenting cells for genetic engineering of immune cells
|
|
WO2018057447A1
(en)
|
2016-09-23 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
|
|
US12499971B2
(en)
|
2016-09-28 |
2025-12-16 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
US12447213B2
(en)
*
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
JP7623784B2
(ja)
|
2016-10-13 |
2025-01-29 |
ジュノー セラピューティクス インコーポレイテッド |
トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
|
|
WO2018071796A2
(en)
|
2016-10-13 |
2018-04-19 |
The Johns Hopkins University |
Compositions and methods for identifying functional anti-tumor t cell responses
|
|
MA46543A
(fr)
|
2016-10-17 |
2019-08-21 |
Bluebird Bio Inc |
Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation
|
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
|
HUE066460T2
(hu)
|
2016-10-26 |
2024-08-28 |
Iovance Biotherapeutics Inc |
A kriokonzervált tumor infiltráló limfociták restimulációja
|
|
AU2017347854B2
(en)
|
2016-10-27 |
2022-12-08 |
Intima Bioscience, Inc. |
Viral methods of T cell therapy
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
US20190262400A1
(en)
|
2016-10-31 |
2019-08-29 |
H. Lee Moffitt Cancer Center And Research Institure, Inc. |
Artificial antigen presenting cells for expanding immune cells for immunotherapy
|
|
JP2019532997A
(ja)
|
2016-11-03 |
2019-11-14 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法とｂｔｋ阻害剤との併用療法
|
|
US11865176B2
(en)
|
2016-11-08 |
2024-01-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of modulating anti-tumor immunity
|
|
WO2018089780A1
(en)
|
2016-11-11 |
2018-05-17 |
Medimmune, Llc |
Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
|
|
KR102618948B1
(ko)
|
2016-11-17 |
2023-12-27 |
이오반스 바이오테라퓨틱스, 인크. |
잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
|
|
CN106658093B
(zh)
|
2016-12-27 |
2019-07-09 |
深圳市九洲电器有限公司 |
机顶盒与服务器的交互方法及系统
|
|
CN110546495B
(zh)
|
2016-12-30 |
2022-11-01 |
加利福尼亚州立大学董事会 |
用于基因组编辑t细胞的选择和传代的方法
|
|
CA3049165A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
MX2019007963A
(es)
|
2017-01-06 |
2019-10-21 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
|
|
CN108342363B
(zh)
|
2017-01-25 |
2021-02-12 |
北京马力喏生物科技有限公司 |
共表达抗msln嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
|
|
CN108342361B
(zh)
|
2017-01-25 |
2020-12-22 |
北京马力喏生物科技有限公司 |
治疗间质素阳性肿瘤的治疗组合物
|
|
WO2018148378A1
(en)
|
2017-02-08 |
2018-08-16 |
Dana-Farber Cancer Institute, Inc. |
Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
|
|
EP3585398A4
(en)
|
2017-02-23 |
2020-08-19 |
Board of Regents of the University of Nebraska |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
US11571459B2
(en)
|
2017-04-03 |
2023-02-07 |
Oncxerna Therapeutics, Inc. |
Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
|
|
US20200377855A1
(en)
|
2017-05-05 |
2020-12-03 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Rapid method for the culture of tumor infiltrating lymphocytes
|
|
KR20200003913A
(ko)
|
2017-05-10 |
2020-01-10 |
이오반스 바이오테라퓨틱스, 인크. |
액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
|
|
AR112072A1
(es)
|
2017-06-05 |
2019-09-18 |
Iovance Biotherapeutics Inc |
Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
|
|
WO2019036815A1
(en)
|
2017-08-24 |
2019-02-28 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
ENHANCEMENT OF CD8 + T LYMPHOCYTES FOR ADOPTIVE CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP))
|
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
|
JP2021501156A
(ja)
|
2017-10-27 |
2021-01-14 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Ｔ細胞疲弊を予防および逆転するためのエピジェネティック標的および転写標的の同定
|
|
CR20200251A
(es)
|
2017-11-17 |
2020-07-17 |
Iovance Biotherapeutics Inc |
Expansión de til de aspirados con aguja fina y biopsias por punción
|
|
EP3714042A4
(en)
|
2017-11-22 |
2021-08-04 |
La Jolla Institute for Allergy and Immunology |
USE AND PRODUCTION OF MODIFIED IMMUNE CELLS
|
|
US20210369775A1
(en)
|
2017-12-15 |
2021-12-02 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
EP3737743A1
(en)
|
2018-01-08 |
2020-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
CN112041433A
(zh)
|
2018-03-15 |
2020-12-04 |
Ksq治疗公司 |
用于改进的免疫疗法的基因调控组合物和方法
|
|
US20190284553A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
CA3094957A1
(en)
|
2018-03-29 |
2019-10-03 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
AU2019252925A1
(en)
|
2018-04-13 |
2020-07-30 |
Sigma-Aldrich Co. Llc. |
Modification of immune-related genomic loci using paired CRISPR nickase ribonucleoproteins
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019217753A1
(en)
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20210236547A1
(en)
|
2018-06-05 |
2021-08-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Rapid production, expansion, and increased purity of car-t cells using beads with protein l
|
|
US20220125891A1
(en)
|
2018-06-06 |
2022-04-28 |
Osaka University |
Method for treating and/or preventing regnase-1-related disease
|
|
KR20210058806A
(ko)
|
2018-06-08 |
2021-05-24 |
로카나바이오 인크. |
Rna 표적화 융합 단백질 조성물 및 사용 방법
|
|
SG11202012015YA
(en)
|
2018-06-08 |
2021-01-28 |
Locanabio Inc |
Compositions and methods for the modulation of adaptive immunity
|
|
BR112020026086A2
(pt)
|
2018-06-21 |
2021-03-23 |
Calico Life Sciences Llc |
inibidores da proteína tirosina fosfatase e métodos de uso destes
|
|
AU2019314888A1
(en)
|
2018-07-31 |
2021-02-18 |
Polybiocept Gmbh |
Production and selection of tumor uber reactive immune cells (TURICs)
|
|
IL281423B2
(en)
|
2018-09-20 |
2024-08-01 |
Iovance Biotherapeutics Inc |
Expansion of TILS from cryopreserved tumor samples
|
|
CN113396216A
(zh)
|
2019-02-04 |
2021-09-14 |
Ksq治疗公司 |
用于改进的免疫疗法的组合基因靶标
|